HSP90AB1 and cancer: 17-AAG treatment was found to reduce cellular proliferation, viability, and migration/invasion, and induce cell death in two different NB cell lines by interfering with different HSP90-dependent molecular pathways involved in cancer and inducing the downregulation of numerous tumorigenic proteins [41].